Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir/Velpatasvir +/- Ribavirin in Japanese Patients with Decompensated Cirrhosis
NCT02996682Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Dec 2016
- Primary completion
- Feb 2018
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of velpatasvir in hepatitis C (HCV), sponsored by Gilead Sciences. Started Dec 2016; status: completed.
02
Drugs
velpatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02996682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02996682.